About the Maxpire IPF Study
The Maxpire IPF Study is a clinical research study looking at a new investigational treatment for people living with Idiopathic Pulmonary Fibrosis (IPF).
IPF is a long-term lung condition that causes scarring of the lungs, making it harder to breathe over time. While there are treatments available that may slow disease progression, IPF currently has no cure. This study aims to explore whether a new treatment may help slow lung scarring, improve lung function, or improve quality of life for people with IPF.
What is the purpose of this study?
The purpose of the Maxpire IPF Study is to:
-
Learn more about the safety of the study medication
-
Understand how the body responds to the treatment
-
Explore whether the treatment may help slow the progression of IPF
Information collected during this study may help improve future treatment options for people with IPF.
What does participation involve?
If you choose to take part, you may be asked to:
-
Attend regular study visits at the hospital or clinic
-
Receive the study treatment or a comparison treatment
-
Have routine health checks such as breathing tests, blood tests, and scans
-
Answer questions about your symptoms and how IPF affects your daily life
All participants will continue to receive appropriate medical care throughout the study.
